Our GWAS analysis is performed using data from the interim release of the first ˜150k UK Biobank (UKB) participants (Supplementary Note): ˜100k individuals from UK Biobank genotyped at ˜800,000 single nucleotide variants (SNVs) with a custom Affymetrix UK Biobank Axiom Array chip and ˜50k individuals genotyped with a custom Affymetrix UK BiLEVE Axiom Array chip from the UK BiLEVE study63, a subset of UKB. SNVs were imputed centrally by UKB using a merged UK10K sequencing + 1000G imputation reference panel. UK Biobank array design and protocols are available on the UK Biobank website.
